Abstract 458P
Background
Venous Thromboembolism (VTE) is a common cardiovascular disease affecting cancer patient with related poor prognosis and short survival. Different scoring systems and certain genetic polymorphisms were used to predict patient's risk for VTE. This study aimed to investigate the association between TSPAN15 (rs78707713) and SLC44A2 (rs2288904) genetic polymorphisms and VTE in cancer patients in correlation with PROTECHT scoring system and survival.
Methods
This case control study was carried out on 100 cancer patients, group I included 50 consecutive cancer patients with VTE, and group II included 50 selected cancer patients without VTE with age and cancer diagnosis matched to group I as a control. Full history taking and clinical examination and all clinical data were recorded. Laboratory investigations including CBC, coagulation profile and analysis of TSPAN15 (rs78707713) and SLC44A2 (rs2288904) SNPs by PCR were assessed. Radiological imaging of VTE by duplex ultrasound, CT pulmonary angiography were done according to the clinical scenario. PROTECHT score and survival analysis were calculated.
Results
Cancer patients with VTE had high tumor grade, increased incidence of metastasis with shorter progression free survival (PFS) compared with cancer patients without VTE. Partial immobilization and hospitalization were significantly associated with the occurrence of VTE in cancer patients. Regarding cancer treatment, the use of gemcitabine-based chemotherapy was associated with an increased risk for VTE. The most frequent SLC44A2 (rs2288904) genotype was GG followed by AG in cancer patients with VTE. Whereas GG and AG genotypes were equally distributed in cancer patients without VTE, The GG genotype had high risk PROTECHT score compared with AA and AG genotypes. The commonest TSPAN15 (rs78707713) genotypes were TC and CC in cancer patients with VTE versus TC and TT in cancer patients without VTE. The CC genotype had high PROTECHT score points compared with TC and TT genotypes. Furthermore, TC and CC cancer patients with VTE had significantly high tumor grade.
Conclusions
Screening of SLC44A2 (rs2288904) and TSPAN15 (rs78707713) genetic variants may enhance the ability to predict VTE risk in cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Menoufeya University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
122P - Distinct transcriptomic immune profiling and clinicopathological features of cribriform morphology in colorectal adenocarcinomas
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
123P - Spatial molecular profiling identifies FGF20 upregulation on cancer-associated fibroblast and FGFR2-PI3K/Akt activation in tumor cells of sporadic early-onset colon cancer
Presenter: Dave Hoon
Session: Poster Display
Resources:
Abstract
124P - Characteristics, prognosis and therapeutic effects of non-V600 BRAF mutated colorectal cancer
Presenter: Lalida Arsa
Session: Poster Display
Resources:
Abstract
125P - Final results of APOLLON-11 and SOYUZ-APOLLON study: Multicentre prospective observational post-authorization study of bevacizumab biosimilar in patients with metastatic colorectal cancer in real-world practice
Presenter: Alexey Tryakin
Session: Poster Display
Resources:
Abstract
126P - From tumor height (TH) to tumor regression grade (TRG) in locally advanced rectal cancers (LARC) during total neadjuvant therapy (TNT): A retrospective analysis
Presenter: Valeria Pusceddu
Session: Poster Display
Resources:
Abstract
127P - A meta-analysis of efficacy and safety from head-to-head first-line (1L) trials of epidermal growth factor receptor inhibitors (EGFRIs) versus bevacizumab in combination with chemotherapy (CT) doublets in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) by sidedness
Presenter: Takayuki Yoshino
Session: Poster Display
Resources:
Abstract
128TiP - A phase II study of cadonilimab + FOLFOXIRI and bevacizumab as initial therapy for unresectable proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC)
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract
140P - Prevalence of claudin-18 isoform 2 (CLDN18.2) positivity in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma in patients (pts) in the Asia region: Phase III SPOTLIGHT and GLOW studies
Presenter: Hoo Hwoei Fen Soo
Session: Poster Display
Resources:
Abstract
141P - Early phase trials outcomes in refractory upper GI cancers: A 10-year analysis from the SCRI UK phase I unit
Presenter: Antonella Cammarota
Session: Poster Display
Resources:
Abstract
142P - The survival impact of the addition of durvalumab to cisplatin/gemcitabine in advanced biliary tract cancer: A real-world, retrospective, multicentric study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract